Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial

IMPORTANCE: ERRB2 (formerly HER2)–positive advanced breast cancer (ABC) remains typically incurable with optimal treatment undefined in later lines of therapy. The chimeric antibody margetuximab shares ERBB2 specificity with trastuzumab but incorporates an engineered Fc region to increase immune act...

Descripción completa

Detalles Bibliográficos
Autores principales: Rugo, Hope S., Im, Seock-Ah, Cardoso, Fatima, Cortés, Javier, Curigliano, Giuseppe, Musolino, Antonino, Pegram, Mark D., Wright, Gail S., Saura, Cristina, Escrivá-de-Romaní, Santiago, De Laurentiis, Michelino, Levy, Christelle, Brown-Glaberman, Ursa, Ferrero, Jean-Marc, de Boer, Maaike, Kim, Sung-Bae, Petráková, Katarína, Yardley, Denise A., Freedman, Orit, Jakobsen, Erik H., Kaufman, Bella, Yerushalmi, Rinat, Fasching, Peter A., Nordstrom, Jeffrey L., Bonvini, Ezio, Koenig, Scott, Edlich, Sutton, Hong, Shengyan, Rock, Edwin P., Gradishar, William J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823434/
https://www.ncbi.nlm.nih.gov/pubmed/33480963
http://dx.doi.org/10.1001/jamaoncol.2020.7932

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823434/
https://www.ncbi.nlm.nih.gov/pubmed/33480963
http://dx.doi.org/10.1001/jamaoncol.2020.7932

Ejemplares similares